X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

ONCOGENE

期刊標題檢索 ONCOGENE 最新評論: After the pre-reception, how long did it take to receive? (2026-07-07)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[ONCOGENE]您好,您是該頁面的第 271692 位訪客。

期刊簡介
期刊名稱ONCOGENE ONCOGENE
LetPub Score
9.0
51 ratings
Rate

Reputation
9.7

Influence
8.5

Speed
8.3

期刊簡稱ONCOGENE
ISSN0950-9232
E-ISSN1476-5594
h-index312
CiteScore
CiteScoreSJRSNIPCiteScore Rank
14.002.4741.584
Subject fieldQuartilesRankPercentile
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Genetics
Q117 / 357
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Molecular Biology
Q136 / 414
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Cancer Research
Q126 / 233

自引率 (2023-2024)1.40%自引率趨勢
掲載範囲
Oncogene aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research. We propagate work that challenges standard conjecture and builds on previous studies, in particular those that lead to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers, and in processes that drive metastatic spread, and provide important insights into cancer biology beyond what has been revealed thus far.
官方網站https://www.nature.com/onc/
在線稿件提交https://mts-onc.nature.com/
開放訪問No
出版商Springer Nature
主題領域医学
出版國/地區ENGLAND
發行頻率週刊
創刊年1997
每年文章數316每年文章數趨勢
黃金OA百分比43.02%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
BIOCHEMISTRY & MOLECULAR BIOLOGYSCIEQ131/328
CELL BIOLOGYSCIEQ133/207
GENETICS & HEREDITYSCIEQ111/192
ONCOLOGYSCIEQ138/333
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0950-9232%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: About 1.0 month(s)
競爭力 *來自作者的數據: About 31.25%
參考鏈接
相關期刊 【ONCOGENE】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    NATURE MEDICINEH-index: 497

    CiteScore: 73.90
    CELLH-index: 705

    CiteScore: 67.80
    Molecular CancerH-index: 103

    CiteScore: 55.00
    Molecular PlantH-index: 85

    CiteScore: 39.20
    NUCLEIC ACIDS RESEARCHH-index: 452

    CiteScore: 29.80
    Molecular CellH-index: 356

    CiteScore: 27.00
    PROGRESS IN LIPID RESEARCHH-index: 132

    CiteScore: 34.60
    TRENDS IN MICROBIOLOGYH-index: 172

    CiteScore: 25.90
    CELL DEATH AND DIFFERENTIATIONH-index: 193

    CiteScore: 29.30
    Nature Chemical BiologyH-index: 182

    CiteScore: 22.80
    學科內最受檢索的期刊 頁面查看次數
    International Journal of Biological Macromolecules2074992
    CELL BIOCHEMISTRY AND BIOPHYSICS1221611
    FASEB JOURNAL801522
    NUCLEIC ACIDS RESEARCH735642
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS728987
    Molecular Cancer417787
    JOURNAL OF BIOLOGICAL CHEMISTRY406613
    International Journal of Biological Sciences352730
    GENETICS AND MOLECULAR RESEARCH350656
    CELL326595
  •  

    ONCOGENE ONCOGENE
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    4    5    6    7    8    9    10    下一頁    末頁  (頁
/31)
  [ONCOGENE] 的評論撰寫評論
作者: Lucy Larkin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-11 22:31:07 評論於
Write again if there is still no news after three months
(0) 讚! | Lucy Larkin

作者: 灵犀谷文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-06 21:47:54 評論於
Review speed: 6.0 | Submission success rate: 75.0
Main research direction: tumor
Experience sharing: I have been under review on oncogene for two months and still haven't heard anything. Has anyone encountered this situation before? Should I send an email to inquire?
(0) 讚! | 灵犀谷文

作者: Lucy Larkin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-17 22:35:10 評論於
Not required, but it's best to back up and keep it yourself
(0) 讚! | Lucy Larkin

作者: 慈悲冬晴


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-03 18:53:48 評論於
How did it end in the end?
(0) 讚! | 慈悲冬晴

作者: 西域昊沅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-31 09:46:44 評論於
Please translate the following paragraph into English and Japanese, respectively, with the titles ":" and ":"
(0) 讚! | 西域昊沅

作者: 苍风己卯


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-23 22:55:49 評論於
Submission hit rate: 50.0
Focus of research: tumor
Experience sharing: What is the situation, everyone?
Editor in Chief Decision Complete 26th Aug 22
Manuscript Decision complete 26th Aug 22
Editor Decision Complete 26th Aug 22
EIC Decision Started 24th Aug 22
Editor Review Completed 24th Aug 22
Waiting for Potential Reviewer Assignment 24th Aug 22
Monitoring Editor Assigned 24th Aug 22
Potential Monitoring Editor Assigned 24th Aug 22
Under Consideration 24th Aug 22
Editor Assigned 23rd Aug 22
Author Approved Converted Files 23rd Aug 22
Submission 23rd Aug 22
(0) 讚! | 苍风己卯

作者: 努力啊大梦菲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-23 19:32:55 評論於
I am wondering the same thing as you
(0) 讚! | 努力啊大梦菲

作者: 努力啊大梦菲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-23 16:33:25 評論於
What happened next?
(0) 讚! | 努力啊大梦菲

作者: 努力啊大梦菲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-23 14:54:33 評論於
My waiting for potential reviewer assignment turned into EIC Decision Started one day later
(0) 讚! | 努力啊大梦菲

作者: 小海宾吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-16 23:38:18 評論於
Usually cancer research only considers oncogene when rejected
(0) 讚! | 小海宾吖

作者: 暴风玉华


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-16 14:08:16 評論於
Review Speed: 3.0 | Submission Hit Rate: 50.0 Emphasis Research Area: Is there a chance 
Experience Sharing: EIC Decision Started 21st Aug 22Editor Review Completed 21st Aug 22Waiting for Potential Reviewer Assignment 17th Aug 22Monitoring Editor Assigned 17th Aug 22Potential Monitoring Editor Assigned 17th Aug 22Under Consideration 17th Aug 22Editor Assigned 9th Aug 22Author Approved Converted Files 9th Aug 22Submission 8th Aug 22
(0) 讚! | 暴风玉华

作者: 岭南鸿骞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-15 23:01:22 評論於
It should not be on the same level
(0) 讚! | 岭南鸿骞

作者: 月河梓美


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-14 16:03:54 評論於
How much does cancer research lag behind oncogene in tumor?
(0) 讚! | 月河梓美

作者: 小海宾吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-05 12:45:35 評論於
Heavy research focus: cancer biology
Sharing experience: Established journals, with somewhat lacking operation. Funding for cancer, in particular, is very competitive, with higher recognition than Molecular Cancer
(0) 讚! | 小海宾吖

作者: 岭南鸿骞


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-25 19:05:44 評論於
Have you found some reviewers?
(0) 讚! | 岭南鸿骞

作者: 九阴凌青


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-21 11:41:20 評論於
Magazines are not required, but reviewers may request them
(0) 讚! | 九阴凌青

作者: 风见秀丽


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-20 23:06:12 評論於
Do you require the original data to be uploaded?
(0) 讚! | 风见秀丽

作者: 风见秀丽


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-20 22:26:23 評論於
Do you need to upload the original data?
(0) 讚! | 风见秀丽

作者: Lucy Larkin


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-28 15:12:25 評論於
Research focus: Tumor experience sharing: A well-established journal, but the quality of published articles in the past two years has been inconsistent, coupled with a certain degree of expansion, the Impact Factor may decrease slightly next year
(0) 讚! | Lucy Larkin

作者: Ann Marion


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-26 10:26:07 評論於
Please log in to the submission system of Oncogene using the account of the corresponding author to access the links
(0) 讚! | Ann Marion

作者: 九阴凌青


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-26 09:38:42 評論於
Research focus: Oncology; Sharing experience on tumor metastasis: The impact factors for 2021 have come out, and I have seen a few have increased. How come it has gone down? If it goes up a little more, won't it pass 10? ?
(0) 讚! | 九阴凌青

作者: Yves Meredith


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-01 22:22:13 評論於
How is everything going from now on?
(0) 讚! | Yves Meredith

作者: 上清怡萱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-05-30 16:11:09 評論於
Do you have to submit to figshare when submitting a manuscript?
(0) 讚! | 上清怡萱

作者: Jay Obadiah


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-15 13:42:02 評論於
Review speed: 1.0 | Submission hit rate: 25.0
Experience sharing: Do we need to resubmit everything when revising? Will the previous status be cleared and turned into a new submission, not caused by my mistake. Please advise
(0) 讚! | Jay Obadiah

作者: 断刀艳清


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-04-14 10:18:47 評論於
How much is the non-OA page charge for the oncogene?
(0) 讚! | 断刀艳清

首頁    上一頁    4    5    6    7    8    9    10    下一頁    末頁  (頁
/31)

開始撰寫 [ONCOGENE] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*